ClinicalTrials.gg
RecruitingNCT07431632FROZEN MIRPEUpdated Feb 24, 2026

Intraoperative Cryoanalgesia Versus Thoracic Epidural Block in MIRPE (Minimally Invasive Repair of Pectus Excavatum)

An interventional study of Cryotherapy and Epidural in Funnel Chest, Pectus Excavatum and Postoperative Pain After Video Assisted Thoracic Surgery, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Nov 2024, registered Jan 2026).
  • Started Nov 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Study summary

The main objective of this study is to compare epidural blockade with cryoanalgesia of the intercostal nerves as an analgesic method in the postoperative period of minimally invasive repair of pectus excavatum (MIRPE).

02

Conditions studied

  • Funnel Chest
  • Pectus Excavatum
  • Postoperative Pain After Video Assisted Thoracic Surgery
  • Postoperative Pain

Keywords

  • cryoanalgesia
  • pectus excavatum
  • funnel chest
  • postoperative pain
  • MIRPE
03

In context

Funnel Chest

79 studies on the registry are indexed under Funnel Chest; 10 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 46 interventional studies indexed under Funnel Chest.

Browse Funnel Chest studies →

Lead sponsor

University of Sao Paulo is the lead sponsor of 1,035 studies on the registry; 95 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Having pectus excavatum;
  2. Having signed the Form for the study.

Exclusion criteria

Exclusion Criteria:

  1. Age \< 13 years at the time of the procedure;
  2. Chronic use of analgesics preoperatively;
  3. Pectus carinatum, Poland syndrome, or other chest wall anomalies;
  4. Previous pectus excavatum repair by any technique;
  5. Previous thoracic surgery;
  6. Congenital heart disease;
  7. Hemorrhagic dyscrasia;
  8. Major anesthetic risk factors or history of previous problems with anesthesia;
  9. Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intraoperative intercostal cryoanalgesia

    Intercostal nerve cryoanalgesia with the Cryo-S Painless device from Metrum Cryoflex

    Device: Cryotherapy

  • Active comparator
    Thoracic epidural block

    Thoracic epidural block

    Procedure: Epidural

Interventions

  • DeviceCryotherapy

    Intraoperative intercostal cryoanalgesia from T3 to T7, billateral

  • ProcedureEpidural

    Thoracic epidural block

06

What researchers measure

Primary outcomes

  1. Length of stay (LOS)

    Length of stay (LOS) is measured in days from postoperative day (POD) 0 until discharge from hospital.

    Time frame: Perioperative/Periprocedural.

Secondary outcomes

  1. Numeric pain scale

    From 0 to 10

    Time frame: Perioperative/Periprocedural

  2. Opioid use

    Oral Morphine Equivalents (OME)

    Time frame: Perioperative/Periprocedural

  3. Postoperative complications

    Surgical complications are registered through an specific scale.

    Time frame: 30 days post-surgery.

  4. Readmissions to the emergency room or hospital readmission

    Compare the frequency and reason for readmissions to the emergency room or hospital admission between groups.

    Time frame: Within 30 days after surgery

  5. Frequency of neuropathic pain

    Incidence of chronic neuropathic pain and paresthesia up to 1 year post-surgery in the group undergoing intercostal cryoablation, using LANNS (Leeds assessment of Neuropathic Symptoms and Signs) scale.

    Time frame: Up to 1 year post-surgery.

  6. Satisfaction with the post-operative result

    Compare patient-reported experience measures (PREMs) between the intercostal cryoablation and thoracic epidural block groups based on postoperative satisfaction at 6 months, assessed using the Single Step Questionnaire (SSQ) score.

    Time frame: Single evaluation during the outpatient follow-up 6 months after surgery.

  7. Cost of hospitalization (in Brazilian Real)

    Compare the total cost of hospitalization during the hospital stay between the two groups.

    Time frame: Perioperative/Periprocedural

07

Study locations

1 of 1 sites recruiting
  • Thoracic Surgery Division, Heart Institute (InCor), University of Sao Paulo Medical School
    São Paulo, São Paulo 05403904, Brazil
    Recruiting
    • Diego Arley G Silva, MD · Sub investigator
    • Miguel L Tedde, MD, PhD · Principal investigator
    • Paulo Manuel Pego-Fernandes, MD, PhD · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.

Of 31 interventional studies with no phase under Funnel Chest, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 68. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Feb 24, 2026
StartActual
Nov 28, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431632
Responsible party
Miguel L. Tedde (Principal Investigator, University of Sao Paulo) — Principal investigator
First posted
Feb 24, 2026
Start date
Nov 28, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Feb 24, 2026

Study contacts

Miguel L Tedde, MD, PhD
Contact
tedde@usp.br
55-11-99653-5030
Diego Arley G Silva, MD
Contact
diegoarley@usp.br
55-83-98650-6438

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion